Skip to main content
. 2019 Jun 13;8(9):4304–4314. doi: 10.1002/cam4.2322

Figure 5.

Figure 5

RANCE‐1 treatment induces tumor changes in expression growth factors and cancer‐immune interface regulators in vivo. In vivo changes in expression levels of proteins of oncological interest, following a 21‐day efficacy trial in Caki‐1 xenograft tumor bearing NOD.CB17‐Prkdc SCID/J mice. The values indicate the percentage of change in expression relative to DMSO treated cells in a Proteome Profiler immunoblotting assay. (*P < 0.05, **P < 0.01, ***P < 0.001). Data represent relative change from 2 separate samples for RANCE‐1 and Vehicle treated mice